All In Biotech

Drug Trial Radar · NCT06824064

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of RBS2418 Plus Best Supportive Care (BSC) in Subjects With Advanced, Metastatic, and Progressive Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 17, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Riboscience, LLC.Industry
Sponsor type
Industry
Collaborators
Tam Anh Research Institute
First posted
Feb 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).

Conditions

  • Metastatic Colorectal Cancer
  • Advanced Colorectal Cancer

Interventions

  • RBS2418Drug

    RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.

  • PlaceboDrug

    Placebo to Match RBS2418

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: From randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.
  2. Overall SurvivalTime frame: From randomization until death from any cause, assessed up to 2 years.

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Christiana Care

    Newark, Delaware · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • SCRI Oncology LLC

    Nashville, Tennessee · Recruiting

  • Community Clinical Trials

    Kingwood, Texas · Recruiting

  • Pan Oncology

    San Juan, Puerto Rico · Recruiting

  • Oncology Hospital

    Ho Chi Minh City, Vietnam · Recruiting

  • Tam Anh, Ha Noi General Hospital

    Hanoi, Hanoi, Vietnam · Recruiting

  • Tam Anh TP. Ho Chi Minh General Hospital

    Ho Chi Minh City, Ho Chi Minh City, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.